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development of various benign and malignant lesions of the skin
and mucosa [1–4]. The current theme issue addresses four
important topics connected with HPV. In the ﬁrst article, the
most frequently used molecular methods for identiﬁcation and
characterization of novel papillomaviruses are reviewed [5].
These methods have resulted in an enormous increase in the
identiﬁcation of novel HPV types in the last few years.
Currently, 200 different HPV types, ranging from HPV-1 to
HPV-204 (HPV-46, HPV-55, HPV-64 and HPV-79 are now
classiﬁed as subtypes), have been ofﬁcially recognized [5].
Two revolutionary technical advances have recently opened
new prospects for the prevention of cervical cancer: molecular
HPV testing and prophylactic HPV vaccination [6,7]. These are
reviewed in the second and third articles of this issue [8,9]. HPV
testing is an invaluable part of guidelines for cervical carcinoma
screening, triage and follow-up after treatment [10,11]. HPV-
based screening is more effective and efﬁcient for the preven-
tion of invasive cervical cancer than cytology-based screening
[11–13], so several countries are now in the process of
switching to HPV-based screening. Given the multitude of
available HPV tests (>175 commercial HPV assays and >100
variants) [14,15], HPV tests that ensure high-quality cervical
cancer screening have to be urgently identiﬁed. In a systematic
review, Arbyn et al. [8] identiﬁed seven commercially available
HPV DNA assays that can currently be recommended as reli-
able tools in HPV-based screening with clinician-collected cer-
vical samples, on the basis of criteria deﬁned by an international
expert team [16]. One E6/E7 mRNA-based assay also fully
fulﬁlled the criteria, although further longitudinal follow-up data
are awaited. Four HPV DNA assays only partially fulﬁlled the
guideline requirements [16].Microbiol Infect 2015; 21: 806–807
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advance for the prevention of cervical cancer. In the third
article of this issue [9], Pils and Joura provide a review of the
milestones in the development of prophylactic HPV vaccines,
starting from an investigational proof-of-concept monovalent
HPV-16 vaccine, and then proceeding through two current
HPV vaccines, i.e. quadrivalent and bivalent, to the recently
licensed nine-valent HPV vaccine [17]. High efﬁcacy in pre-
venting high-grade precursors of cervical, vulvar, vaginal and
anal cancer related to the vaccine HPV types (and genital warts
in the case of quadrivalent and nine-valent vaccines) led recently
to a paradigm shift from a female-only cervical cancer vaccine
to a vaccine for the prevention of several HPV-related diseases
and cancers in both genders. Current evidence suggests that
vaccination prior to the start of sexual activity is most effective,
and that gender-neutral HPV vaccination is the most logical way
forwards. Thus, Garland et al. [18] provide and discuss ideas of
how best to measure the effectiveness of male HPV vaccine
programmes. With the introduction of gender-neutral HPV
vaccination, post-vaccine monitoring will be critical for evalu-
ating the incremental impact of male vaccination. In contrast to
established cervical cancer screening programmes, which we
are also using to monitor the real-life effectiveness of HPV
vaccines, population-wide screening for HPV infection or HPV-
related disease in males is not feasible, and could not be rec-
ommended. Real-time monitoring of HPV vaccine effectiveness
in males will thus require dedicated surveillance strategies.
Garland et al. propose that monitoring the prevalence of
circulating anogenital HPV types with a sentinel surveillance
model could offer a good surrogate marker of early vaccine
effectiveness in males [18]. However, such an approach re-
quires careful consideration of the most appropriate anatomical
sites from which to collect specimens, the best sampling
methods, and the most sensitive HPV assays to use [18].
A combined approach of universal and gender-neutral HPV
vaccination, with screening when appropriate, is the most
compelling strategy for signiﬁcantly reducing the burden of
HPV-related diseases and cancers in both genders. In the case ofious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Editorial 807cervical cancer, HPV vaccination and screening are not mutually
exclusive, but act synergistically by intervening at different
points in the natural history of cervical cancer, and currently
imply actions in women of different ages. When adequately
combined, these two prevention options have the potential to
dramatically reduce cervical cancer incidence and mortality; the
magnitude of this potential is not currently rivalled for any
other neoplastic disease [19]. However, at present, these two
powerful prevention strategies remain apparently unconnected,
and no country has yet adopted different screening policies for
vaccinated and unvaccinated women. Therefore, the time is
now right to begin to evaluate strategies that combine HPV
vaccination and cervical cancer screening in the best possible
way. HPV-based screening is probably the only rational way
forwards for screening primary vaccinated cohorts, but the
questions of when to start and how frequently to screen remain
open [10]. Prudent and synergistic use of HPV vaccination and
HPV-based screening will probably be the hallmark of success in
the future, but uncoordinated adoption of these technologies in
opportunistic and non-universal conditions will only heighten
the inequality that has characterized cervical cancer prevention
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